CA3099579A1 - Triazolopyrimidine compounds and their use in treating cancer - Google Patents
Triazolopyrimidine compounds and their use in treating cancer Download PDFInfo
- Publication number
- CA3099579A1 CA3099579A1 CA3099579A CA3099579A CA3099579A1 CA 3099579 A1 CA3099579 A1 CA 3099579A1 CA 3099579 A CA3099579 A CA 3099579A CA 3099579 A CA3099579 A CA 3099579A CA 3099579 A1 CA3099579 A1 CA 3099579A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- triazolo
- pyrrolidin
- phenyl
- trimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670075P | 2018-05-11 | 2018-05-11 | |
| US62/670,075 | 2018-05-11 | ||
| PCT/EP2019/062020 WO2019215316A1 (en) | 2018-05-11 | 2019-05-10 | Triazolopyrimidine compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3099579A1 true CA3099579A1 (en) | 2019-11-14 |
Family
ID=66484070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3099579A Pending CA3099579A1 (en) | 2018-05-11 | 2019-05-10 | Triazolopyrimidine compounds and their use in treating cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11084827B2 (https=) |
| EP (2) | EP4134368A1 (https=) |
| JP (1) | JP7418353B2 (https=) |
| KR (1) | KR102863374B1 (https=) |
| CN (3) | CN112469721B (https=) |
| AR (1) | AR115384A1 (https=) |
| AU (1) | AU2019264826B2 (https=) |
| BR (1) | BR112020023068A2 (https=) |
| CA (1) | CA3099579A1 (https=) |
| DK (1) | DK3790879T3 (https=) |
| ES (1) | ES2927244T3 (https=) |
| MX (1) | MX2020012058A (https=) |
| PT (1) | PT3790879T (https=) |
| TW (1) | TWI823932B (https=) |
| UY (1) | UY38228A (https=) |
| WO (1) | WO2019215316A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI823932B (zh) * | 2018-05-11 | 2023-12-01 | 中國大陸商迪哲（江蘇）醫藥有限公司 | 三唑并嘧啶化合物及其在治療癌症中之用途 |
| WO2021174176A1 (en) * | 2020-02-28 | 2021-09-02 | Remix Therapeutics Inc. | Pyridazine dervatives for modulating nucleic acid splicing |
| US20230192704A1 (en) * | 2020-05-21 | 2023-06-22 | Teon Therapeutics, Inc. | Monocarboxylic acid transporter 4 (mct4) modulators and uses thereof |
| WO2021249969A1 (en) * | 2020-06-10 | 2021-12-16 | Merck Patent Gmbh | Combination product for the treatment of cancer diseases |
| WO2022090527A1 (en) | 2020-11-02 | 2022-05-05 | Ares Trading S.A. | Combination treatment of cancer |
| WO2022243573A1 (en) | 2021-05-21 | 2022-11-24 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use |
| WO2022243574A1 (en) | 2021-05-21 | 2022-11-24 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use |
| CN120699024A (zh) * | 2024-03-25 | 2025-09-26 | 北京福元医药股份有限公司 | Mct4抑制剂及其药物组合物和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040072746A1 (en) * | 2001-10-16 | 2004-04-15 | Michael Sullivan | Inhibitors of monocarboxylate transport |
| SE0300119D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| DE102005034905A1 (de) | 2005-07-26 | 2007-02-01 | Federal-Mogul Nürnberg GmbH | Verfahren zur Herstellung eines Kolbens für einen Verbrennungsmotor sowie Kolben für einen Verbrennungsmotor |
| WO2010089580A1 (en) | 2009-02-06 | 2010-08-12 | Astrazeneca Ab | Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4 |
| WO2011114148A1 (en) | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
| US10328078B2 (en) * | 2015-01-22 | 2019-06-25 | The Scripps Research Institute | Pteridine dione monocarboxylate transporter inhibitors |
| CA2974697A1 (en) * | 2015-01-22 | 2016-07-28 | The Scripps Research Institute | Pyrimidine-2,4-(1h,3h)-dione derivatives and pharmaceutical compositions thereof and their use as inhibitors of monocarboxylate transporters |
| BR112017026535B1 (pt) * | 2015-06-12 | 2023-12-19 | Vettore, LLC | Composto e composição farmacêutica |
| EP3455207A4 (en) * | 2016-05-12 | 2019-10-09 | Regents of the University of Minnesota | INDOL AND INDAZOCYANOCINNAMATE COMPOUNDS AND THERAPEUTIC USES THEREOF |
| TWI823932B (zh) * | 2018-05-11 | 2023-12-01 | 中國大陸商迪哲（江蘇）醫藥有限公司 | 三唑并嘧啶化合物及其在治療癌症中之用途 |
-
2019
- 2019-05-07 TW TW108115719A patent/TWI823932B/zh active
- 2019-05-10 CN CN201980046079.2A patent/CN112469721B/zh active Active
- 2019-05-10 DK DK19723404.0T patent/DK3790879T3/da active
- 2019-05-10 AR ARP190101254A patent/AR115384A1/es unknown
- 2019-05-10 EP EP22181542.6A patent/EP4134368A1/en active Pending
- 2019-05-10 MX MX2020012058A patent/MX2020012058A/es unknown
- 2019-05-10 EP EP19723404.0A patent/EP3790879B1/en active Active
- 2019-05-10 JP JP2020563691A patent/JP7418353B2/ja active Active
- 2019-05-10 CN CN202210528893.1A patent/CN115028637B/zh active Active
- 2019-05-10 BR BR112020023068-5A patent/BR112020023068A2/pt active Search and Examination
- 2019-05-10 WO PCT/EP2019/062020 patent/WO2019215316A1/en not_active Ceased
- 2019-05-10 UY UY38228A patent/UY38228A/es not_active Application Discontinuation
- 2019-05-10 CA CA3099579A patent/CA3099579A1/en active Pending
- 2019-05-10 ES ES19723404T patent/ES2927244T3/es active Active
- 2019-05-10 PT PT197234040T patent/PT3790879T/pt unknown
- 2019-05-10 CN CN202210528891.2A patent/CN115028636A/zh active Pending
- 2019-05-10 AU AU2019264826A patent/AU2019264826B2/en active Active
- 2019-05-10 KR KR1020207035470A patent/KR102863374B1/ko active Active
-
2020
- 2020-11-11 US US17/095,729 patent/US11084827B2/en active Active
-
2021
- 2021-07-05 US US17/367,450 patent/US11851432B2/en active Active
-
2023
- 2023-11-14 US US18/508,257 patent/US12503473B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020023068A2 (pt) | 2021-02-09 |
| EP4134368A1 (en) | 2023-02-15 |
| EP3790879B1 (en) | 2022-06-29 |
| AR115384A1 (es) | 2021-01-13 |
| CN112469721A (zh) | 2021-03-09 |
| EP3790879A1 (en) | 2021-03-17 |
| ES2927244T3 (es) | 2022-11-03 |
| US20210087196A1 (en) | 2021-03-25 |
| CN115028636A (zh) | 2022-09-09 |
| WO2019215316A1 (en) | 2019-11-14 |
| PT3790879T (pt) | 2022-08-26 |
| AU2019264826A1 (en) | 2020-11-26 |
| CN115028637A (zh) | 2022-09-09 |
| US12503473B2 (en) | 2025-12-23 |
| KR102863374B1 (ko) | 2025-09-22 |
| US11851432B2 (en) | 2023-12-26 |
| AU2019264826B2 (en) | 2024-05-23 |
| US11084827B2 (en) | 2021-08-10 |
| US20210340150A1 (en) | 2021-11-04 |
| KR20210013078A (ko) | 2021-02-03 |
| CN115028637B (zh) | 2024-03-22 |
| DK3790879T3 (da) | 2022-08-29 |
| US20240217980A1 (en) | 2024-07-04 |
| JP7418353B2 (ja) | 2024-01-19 |
| JP2021523177A (ja) | 2021-09-02 |
| TW202015674A (zh) | 2020-05-01 |
| TWI823932B (zh) | 2023-12-01 |
| CN112469721B (zh) | 2022-06-07 |
| MX2020012058A (es) | 2021-02-26 |
| UY38228A (es) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12503473B2 (en) | Triazolopyrimidine compounds and their use in treating cancer | |
| AU2020252116B2 (en) | Estrogen receptor degrading protacs | |
| US9428503B2 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer | |
| EP3053923B1 (en) | Triazolopyrazine derivatives as tyrosin kinase inhibitors | |
| US11034696B2 (en) | Compounds for inhibiting LRRK2 kinase activity | |
| CA3219002A1 (en) | Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use | |
| AU2026200481A1 (en) | 4-(Imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives | |
| AU2017359561A1 (en) | Pyrimidinone derivatives as Cdc7 inhibitors | |
| RU2793249C2 (ru) | Триазолпиримидиновые соединения и их применение в лечении рака | |
| HK40088382A (en) | Triazolopyrimidine compounds and their use in treating cancer | |
| HK40047025B (en) | Triazolopyrimidine compounds and their use in treating cancer | |
| HK40047025A (en) | Triazolopyrimidine compounds and their use in treating cancer | |
| HK40080418A (en) | Triazolopyrimidine compounds and their use in treating cancer | |
| HK40080417A (en) | Triazolopyrimidine compounds and their use in treating cancer | |
| HK40080417B (zh) | 三唑并嘧啶化合物和其用於治疗癌症的用途 | |
| HK40047024A (en) | Triazolopyrimidine compounds and their use in treating cancer | |
| KR20250100670A (ko) | 융합 바이사이클릭 화합물 및 이의 Mer 및 Axl 억제제로서의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231227 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250128 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250507 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250507 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250526 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250526 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250529 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250529 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260305 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260305 |